Comments to FDA: Security Requirements for PSE, Ephedrine, and PPA

Share page:
Docket Number:

This letter is submitted on behalf of CHPA, FMI, HDMA, and NACDS. The purpose of the letter is to express our united concern that the DEA’s proposed rule is not supported by existing evidence and will impose a significant burden on the regulated industry.